In the Claims

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

- 1. (Original) A strain of *Francisella* species wherein a gene which encodes an enzyme in the purine pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as a live prophylactic or therapeutic vaccine against infection by said *Francisella* species.
- 2. (Original) A strain according to claim 1 wherein the gene encodes an enzyme, which is active early in the purine pathway.
- 3. (Original) A strain according to claim 1 wherein the gene is one of the first six enzymes in the purine pathway.
- 4. (Currently Amended) A strain according to claim 1, 2 or 3 Claim 1 wherein the gene is purF.
- 5. (Currently Amended) A strain according to any of claims 1 to 4 Claim 1 wherein said gene is inactivated by complete or partial deletion mutation or by insertional mutation.
- 6. (Currently Amended) A strain according to any one of the preceding claims Claim 1 which is a strain of Francisella tularensis.
- 7. (Original) A strain according to claim 6 which is a strain of *Francisella tularensis* subspecies *tularensis*.
- 8. (Original) A strain according to claim 6 which is a strain of *Francisella tularensis* subspecies *novicida*.
- 9. (Original) A pharmaceutical composition comprising a live strain of *Francisella* species wherein a gene, which encodes an enzyme in the purine pathway, has been inactivated, and which is able to produce a protective immune response in an animal, in combination with a pharmaceutically acceptable carrier.

- 10. (Currently Amended) A composition according to claim The pharmaceutical composition of Claim 9 wherein the gene encodes an enzyme, which is active early in the purine pathway.
- 11. (Currently Amended) A composition according to claim 9 or 10 The pharmaceutical composition of Claim 9 wherein the gene is one of the first six enzymes in the purine pathway.
- 12. (Currently Amended) A composition according to any of claims 9, 10 or 11 The pharmaceutical composition of Claim 9 wherein the gene is purF.
- 13. (Currently Amended) A composition according to any of claims 9 to 12wherein The pharmaceutical composition of Claim 9 wherein said gene is inactivated by complete or partial deletion mutation or by insertional mutation.
- 14. (Currently Amended) A pharmaceutical composition according to any one of claims 9 to 13 The pharmaceutical composition of Claim 9 wherein the strain is a strain of Francisella tularensis.
- 15. (Original) A pharmaceutical composition according to claim 13 wherein the strain is a strain of Francisella tularensis subspecies tularensis or a strain of Francisella tularensis subspecies novicida.

Claims 16-22 (Cancelled).

- 23. (Currently Amended) A method of preventing or treating infection by a Francisella species, which method comprises administering to an animal an effective amount of a live strain according to any one of claims 1 to 8 or a composition according to any one of claims 9 to 15 of Francisella species, in which a gene that encodes an enzyme in the purine pathway has been inactivated, to produce a protective immune response in an animal.
- Original) A method according to claim 23 for preventing or treating infection by Francisella tularensis, wherein the strain of Francisella species used in the method is a strain of Francisella tularensis subspecies tularensis or Francisella tularensis subspecies novicida.

U.S. National Phase of PCT/GB2004/001264

Filed: 27 September 2005

PRELIMINARY AMENDMENT

25. (Currently Amended) A method for preparing a strain according to any one of claims

1 to 8, which comprises transforming a strain of Francisella species so as to

inactivate said gene The strain of Claim 1, wherein the gene is inactivated using

cryotransformation.

26. (Original) A strain of Francisella tularensis subspecies tularensis wherein a gene that encodes a purF gene has been inactivated.